OR WAIT null SECS
Clinicians at ACAAI 2026 will see late-breaking HAE, anaphylaxis, urticaria, and food allergy data, plus exclusive expert interviews.
The American College of Allergy, Asthma & Immunology (ACAAI) 2026 Annual Scientific Meeting will convene in Phoenix, Arizona, from Thursday, November 12, to Monday, November 16, bringing together allergy and immunology clinicians at the Phoenix Convention Center.¹ Registrants will have on-demand access to > 50 hours of recorded sessions.¹
November 12 - 16, 2026, at the Phoenix Convention Center in Phoenix, Arizona.
When are the late-breakers?
All on Saturday, November 14, from 4:30 pm to 6:00 pm MST.
What’s new in hereditary angioedema?
New data on deucrictibant, lonvoguran ziclumeran, and lanadelumab.
What’s new in anaphylaxis?
New data on intranasal and sublingual epinephrine, plus epinephrine management in schools.
What’s new in urticaria?
New data on remibrutinib and barzolvolimab.
This year’s meeting theme is “Building Bridges for the Future.”¹ Late-breaking science is concentrated on Saturday, November 14, with abstracts spanning hereditary angioedema (HAE), anaphylaxis, urticaria, systemic mastocytosis, food allergy, and ocular allergy.
The HCPLive editorial team will be on-site throughout the meeting, providing written coverage of practice-changing data and video interviews with leading allergy and immunology experts, including Michael S. Blaiss, MD (Augusta University); William R. Lumry, MD (UT Southwestern Medical School); Thanai Pongdee, MD (Mayo Clinic); Giselle S. Mosnaim, MD (University of Chicago); and Aleena Banerji, MD (Mass General Brigham). You can follow HCPLive’s comprehensive ACAAI 2026 coverage here. Check out what to expect from this year’s meeting below.
1. Enhanced Absorption of Intranasal Powder Epinephrine (FMXIN002) After Double Dose in Adults With Allergic Rhinitis
Presenter: Michael S. Blaiss, MD
Time: 4:33 PM – 4:43 PM MST
FMXIN002 is an investigational needle-free intranasal powder formulation of epinephrine from Nasus Pharma. This study evaluates epinephrine absorption after a double dose in adults with allergic rhinitis.
2. Dibutepinephrine Pharmacokinetics/Pharmacodynamics in Patients With and Without Symptoms of a Type I Allergic Reaction
Presenter: Jay A. Lieberman, MD
Time: 4:43 PM – 4:53 PM MST
Dibutepinephrine is an epinephrine prodrug delivered as a sublingual film by Aquestive Therapeutics. This analysis compares pharmacokinetic and pharmacodynamic (PK/PD) profiles in patients with and without symptoms of a type I allergic reaction.
3. Efficacy and Safety of Freneslerbart-Mevonlerbart (REGN-2Cat) on Ocular Manifestations of Cat Allergen-Induced Allergic Conjunctivitis
Presenter: Deepti Deshpande, MD, MPH
Time: 4:53 PM – 5:03 PM
Freneslerbart-mevonlerbart (REGN-2Cat) is an investigational antibody combination from Regeneron. This late-breaker reports efficacy and safety outcomes on the ocular manifestations of cat allergen-induced allergic conjunctivitis.
4. Symptom Severity Reduction and QoL Improvement With Avapritinib in Indolent Systemic Mastocytosis Through 4 Years
Presenter: Thanai Pongdee, MD
Time: 5:13 PM – 5:23 PM MST
Avapritinib (Ayvakit) is a selective KIT D816V inhibitor approved for adults with indolent systemic mastocytosis. Drawing on long-term follow-up from the PIONEER trial, this analysis reports symptom severity and quality-of-life outcomes through 4 years of treatment.
5. Pharmacokinetics and Pharmacodynamics of Top of Tongue Placement of Dibutepinephrine Sublingual Film
Presenter: Matthew Greenhawt, MD, MBA, MSc
Time: 5:23 PM – 5:33 PM MST
This companion analysis evaluates the PK/PD profile of dibutepinephrine sublingual film when the film is placed on top of the tongue instead of beneath it.
6. Oral Deucrictibant Extended-Release Tablet for Prophylaxis of Hereditary Angioedema Attacks: The Phase 3 CHAPTER-3 Trial
Presenter: Marc A. Riedl, MD, MS
Time: 5:33 PM – 5:43 PM MST
Deucrictibant is an oral bradykinin B2 receptor antagonist from Pharvaris. CHAPTER-3 randomized 85 adolescents and adults from 21 countries 2:1 to deucrictibant extended-release (XR) 40 mg once daily or placebo, enrolling patients with HAE type 1, type 2, and normal C1 inhibitor.² In topline data, deucrictibant XR reduced the mean monthly attack rate by 83% compared with placebo (P <.0001).²
7. Remibrutinib Showed Sustained Efficacy and Favorable Safety Profile Through Week 52 in Chronic Inducible Urticaria
Presenter: Giselle S. Mosnaim, MD, MS
Time: 5:43 PM – 5:53 PM MST
Remibrutinib (Rhapsido) is an oral Bruton tyrosine kinase (BTK) inhibitor. This analysis reports efficacy and safety through week 52 in patients with chronic inducible urticaria.
8. Impact of Lanadelumab Prophylaxis on Quality of Life in Pediatric Hereditary Angioedema Patients and Caregivers
Presenter: William R. Lumry, MD
Time: 4:33 PM – 4:43 PM MST
Lanadelumab (Takhzyro) is a monoclonal antibody inhibiting plasma kallikrein, used for HAE prophylaxis. This analysis evaluates quality-of-life outcomes in pediatric patients with HAE and in their caregivers.
9. Four-Year Durability/Safety of Lonvoguran Ziclumeran (Lonvo-z) 50 mg in Patients With Hereditary Angioedema
Presenter: Danny M. Cohn, MD, PhD
Time: 4:43 PM – 4:53 PM MST
Lonvoguran ziclumeran (lonvo-z) is an investigational, one-time, in vivo CRISPR-based gene-editing therapy from Intellia Therapeutics. This analysis reports 4-year durability and safety outcomes with the 50 mg dose.
10. Attack-Free and Long-Term Prophylaxis-Free Status Following Treatment With Lonvoguran Ziclumeran in Hereditary Angioedema
Presenter: Emel Aygören-Pürsün, MD
Time: 4:53 PM – 5:03 PM MST
This abstract builds on the durability data and assesses how many patients remained attack-free and free of long-term prophylaxis after a single lonvo-z treatment.
11. Precision Immunotherapy to Treat Peanut Allergy: Topline Phase 2 Results of PVX108 in Children
Presenter: Brian P. Vickery, MD
Time: 5:23 PM – 5:33 PM MST
PVX108 is an investigational peptide immunotherapy for peanut allergy from Aravax. This abstract reports topline phase 2 results in children.
12. Dupilumab Versus Omalizumab in Type-2-High Patients With Chronic Rhinosinusitis With Nasal Polyps and Coexistent Asthma
Presenter: Michael E. Wechsler, MD, MMSc
Time: 5:33 PM – 5:43 PM MST
This late-breaker from the EVEREST trial compares dupilumab (Dupixent) with omalizumab (Xolair) in patients with type 2-high chronic rhinosinusitis with nasal polyps and coexisting asthma.
References
Related Content:
